×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EVFM – evofem biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EVFM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
8/15
08:18 am
evfm
Evofem Biosciences, Inc. (NASDAQ: EVFM) had its price target raised by analysts at HC Wainwright to $4.00. They now have a "buy" rating on the stock.
Low
Report
Evofem Biosciences, Inc. (NASDAQ: EVFM) had its price target raised by analysts at HC Wainwright to $4.00. They now have a "buy" rating on the stock.
8/10
08:23 pm
evfm
Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022
Medium
Report
Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022
8/9
08:00 am
evfm
Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
High
Report
Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
8/5
12:01 am
evfm
Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q2 2022 Results - Earnings Call Transcript [Seeking Alpha]
High
Report
Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q2 2022 Results - Earnings Call Transcript [Seeking Alpha]
8/4
04:01 pm
evfm
Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance
Medium
Report
Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance
8/3
08:24 am
evfm
Evofem Biosciences Strengthens Board of Directors
High
Report
Evofem Biosciences Strengthens Board of Directors
8/1
08:47 am
evfm
Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women
Medium
Report
Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women
7/29
08:24 am
evfm
Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals
High
Report
Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
8/12
05:23 pm
evfm
Form 10-Q Evofem Biosciences, Inc. For: Jun 30
Low
Report
Form 10-Q Evofem Biosciences, Inc. For: Jun 30
8/10
04:17 pm
evfm
Form SC 13G/A Evofem Biosciences, Inc. Filed by: Cox Todd Stewart
Low
Report
Form SC 13G/A Evofem Biosciences, Inc. Filed by: Cox Todd Stewart
8/10
08:53 am
evfm
Form 8-K Evofem Biosciences, Inc. For: Aug 09
High
Report
Form 8-K Evofem Biosciences, Inc. For: Aug 09
8/8
05:27 pm
evfm
Form 3 Evofem Biosciences, Inc. For: Aug 02 Filed by: Yip Jenny C.
High
Report
Form 3 Evofem Biosciences, Inc. For: Aug 02 Filed by: Yip Jenny C.
8/4
05:03 pm
evfm
Form 8-K Evofem Biosciences, Inc. For: Aug 04
High
Report
Form 8-K Evofem Biosciences, Inc. For: Aug 04
8/4
04:39 pm
evfm
Form 8-K Evofem Biosciences, Inc. For: Aug 04
Medium
Report
Form 8-K Evofem Biosciences, Inc. For: Aug 04
8/3
08:25 am
evfm
Form 8-K Evofem Biosciences, Inc. For: Aug 02
High
Report
Form 8-K Evofem Biosciences, Inc. For: Aug 02
7/19
04:32 pm
evfm
Form SC 13G Evofem Biosciences, Inc. Filed by: Cox Todd Stewart
Low
Report
Form SC 13G Evofem Biosciences, Inc. Filed by: Cox Todd Stewart
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/7
Form 424B3 Evofem Biosciences, Inc.
24.7%
5/10 Form DEFR14A Evofem Biosciences, Inc. 16.9%
12/2 Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women 12.3%
3/25 Evofem Biosciences Adopts Shareholder Rights Agreement 10.2%
4/17 Form 8-K Evofem Biosciences, Inc. For: Apr 14 9.8%
5/29 Evofem Biosciences Inc (NASDAQ: EVFM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.8%
5/28 Evofem Biosciences Inc (NASDAQ: EVFM) was given a new $9.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 6.5%
5/14 Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference 6.3%
3/30 Form DEF 14A Evofem Biosciences, Inc. For: May 12 6.0%
1/10 Form 8-K Evofem Biosciences, Inc. For: Jan 10 5.7%
5/10 Form DEFR14A Evofem Biosciences, Inc. 16.9%
12/2 Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women 12.3%
3/25 Evofem Biosciences Adopts Shareholder Rights Agreement 10.2%
4/17 Form 8-K Evofem Biosciences, Inc. For: Apr 14 9.8%
5/29 Evofem Biosciences Inc (NASDAQ: EVFM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.8%
5/28 Evofem Biosciences Inc (NASDAQ: EVFM) was given a new $9.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 6.5%
5/14 Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference 6.3%
3/30 Form DEF 14A Evofem Biosciences, Inc. For: May 12 6.0%
1/10 Form 8-K Evofem Biosciences, Inc. For: Jan 10 5.7%
TOP News Decliners
7/1
Evofem Biosciences Added to Russell 3000® Index
-16.5%
12/31 Form 4 Evofem Biosciences, Inc. For: Dec 31 Filed by: Lynch Thomas G -13.5%
12/2 UPDATE: Evofem Biosciences stock soars 27% premarket on news of positive results in trial of drugs for STDs [MarketWatch] -12.4%
3/12 Q4/2019 12/31/2019 EPS -0.270 ZacksConsensus -0.290 ActVsEst 0.020 - Beat -12.0%
6/24 Form S-3 Evofem Biosciences, Inc. -9.7%
4/28 Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020 -7.3%
4/27 Evofem Biosciences Secures up to $25 Million in Convertible Note Financing -6.6%
5/12 Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.0%
4/2 Evofem Biosciences Inc (NASDAQ: EVFM) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -5.3%
11/26 Form 8-K Evofem Biosciences, Inc. For: Nov 26 -5.2%
12/31 Form 4 Evofem Biosciences, Inc. For: Dec 31 Filed by: Lynch Thomas G -13.5%
12/2 UPDATE: Evofem Biosciences stock soars 27% premarket on news of positive results in trial of drugs for STDs [MarketWatch] -12.4%
3/12 Q4/2019 12/31/2019 EPS -0.270 ZacksConsensus -0.290 ActVsEst 0.020 - Beat -12.0%
6/24 Form S-3 Evofem Biosciences, Inc. -9.7%
4/28 Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020 -7.3%
4/27 Evofem Biosciences Secures up to $25 Million in Convertible Note Financing -6.6%
5/12 Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.0%
4/2 Evofem Biosciences Inc (NASDAQ: EVFM) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -5.3%
11/26 Form 8-K Evofem Biosciences, Inc. For: Nov 26 -5.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: